ALIM Alimera Sciences Inc.

1.06
0  0%
Previous Close 1.06
Open 1.06
Price To Book -2.72
Market Cap 74283611
Shares 70,078,878
Volume 65,448
Short Ratio
Av. Daily Volume 103,526

NewsSee all news

  1. Edited Transcript of ALIM earnings conference call or presentation 19-Feb-19 2:00pm GMT
  2. Will Alimera Sciences (ALIM) Report Negative Q4 Earnings? What You Should Know
  3. Alimera Sciences, Inc. to Host Earnings Call
  4. Alimera Sciences Reports Record Fourth Quarter and 2018 Results
  5. Alimera Sciences Announces Approval for ILUVIEN(R) in Lebanon

SEC filingsSee all SEC filings

  1. 8-K - Current report 19613333
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 19608279
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19606955
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19606325
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604948

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema

Latest News

  1. Edited Transcript of ALIM earnings conference call or presentation 19-Feb-19 2:00pm GMT
  2. Will Alimera Sciences (ALIM) Report Negative Q4 Earnings? What You Should Know
  3. Alimera Sciences, Inc. to Host Earnings Call
  4. Alimera Sciences Reports Record Fourth Quarter and 2018 Results
  5. Alimera Sciences Announces Approval for ILUVIEN(R) in Lebanon
  6. Alimera Sciences to Report Fourth Quarter and Full Year 2018 Results on February 18, 2019
  7. Eye implant is helping treat vision loss in diabetics
  8. Alimera Sciences Affirms Record 2018 Revenues
  9. What Type Of Shareholder Owns Alimera Sciences, Inc.’s (NASDAQ:ALIM)?
  10. Alimera Sciences Announces Pricing Approval For ILUVIEN(R) in the U.A.E.
  11. Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer
  12. Alimera Sciences Announces Canadian Regulatory Approval for ILUVIEN(R)
  13. Edited Transcript of ALIM earnings conference call or presentation 6-Nov-18 2:00pm GMT
  14. Alimera Sciences to Present at Upcoming Investor Conferences
  15. Alimera Sciences (ALIM) Reports Q3 Loss, Tops Revenue Estimates
  16. Alimera Sciences: 3Q Earnings Snapshot
  17. Alimera Sciences Reports Third Quarter 2018 Results
  18. Alimera Sciences to Report Third Quarter 2018 Results November 5, 2018
  19. Alimera Sciences Announces Six ILUVIEN(R) Posters to be Presented at 2018 American Academy of Ophthalmology

SEC Filings

  1. 8-K - Current report 19613333
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 19608279
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19606955
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19606325
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604948
  6. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19601922
  7. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 19600529
  8. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19602917
  9. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19602759
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19590929